Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that serves as a master regulator of neuroinflammation in the central nervous system. Produced primarily by microglia, astrocytes, and infiltrating immune cells, IL-1β drives a cascade of inflammatory responses that contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions 1. The cytokine is encoded by the IL1B gene on chromosome 2q14.1 and is synthesized as an inactive propeptide (pro-IL-1β) that requires proteolytic cleavage by caspase-1 within the NLRP3 inflammasome complex to become biologically active.
| Protein Name | Interleukin-1 Beta (IL-1β) |
|---|
| Gene | [IL1B](/genes/il1b) |
|---|
| UniProt ID | [P01584](https://www.uniprot.org/uniprot/P01584) |
|---|
| Molecular Weight | ~31 kDa (active form) |
|---|
| Protein Length | 269 amino acids (active) |
|---|
| Protein Fold | Beta-trefoil fold |
|---|
| Subcellular Localization | Secreted, cytosol |
|---|
| Expression | Microglia, astrocytes, neurons, immune cells |
|---|
¶ Molecular Biology and Processing
¶ Gene Structure and Regulation
The IL1B gene spans approximately 9.5 kb and consists of 7 exons. Expression is tightly regulated at multiple levels:
- Transcriptional Control: NF-κB and AP-1 binding sites in the IL1B promoter drive transcription in response to pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and other inflammatory signals
- Post-transcriptional Regulation: mRNA stability elements and microRNA binding (e.g., miR-155) modulate IL1B mRNA half-life
- Epigenetic Control: DNA methylation and histone modifications influence IL1B expression in different cell types
¶ Protein Processing and Maturation
IL-1β is synthesized as a 31 kDa propeptide (pro-IL-1β, amino acids 1-269) that lacks biological activity. Activation requires proteolytic cleavage:
- Inflammasome Assembly: Pattern recognition receptors (e.g., NLRP3) detect cellular stress signals and assemble the inflammasome complex containing procaspase-1
- Caspase-1 Activation: Autocatalysis converts procaspase-1 to active caspase-1
- Pro-IL-1β Cleavage: Caspase-1 cleaves pro-IL-1β between Asp116 and Ala117, releasing the 17 kDa active fragment (amino acids 117-269)
- Secretion: The active IL-1β is secreted via gasdermin D pores or alternative pathways
¶ Receptor Binding and Signaling
IL-1β signals through the IL-1 receptor complex:
- IL-1 Receptor Type I (IL-1R1): The signaling receptor, requiring the IL-1 receptor accessory protein (IL-1RAP) for signal transduction
- IL-1 Receptor Type II (IL-1R2): A decoy receptor that sequesters IL-1β and prevents signaling
- IL-1 Receptor Antagonist (IL-1RA): A natural antagonist that blocks IL-1R1 binding
Upon binding, the IL-1R1/IL-1RAP complex activates:
- MyD88-dependent signaling: Adaptor protein MyD88 recruits IRAK kinases
- NF-κB activation: TRAF6 ubiquitination leads to IKK complex activation and IκB degradation
- MAPK activation: JNK, p38, and ERK pathways are also activated
- Gene transcription: Pro-inflammatory genes including IL6, TNF, and itself are expressed
Under normal conditions, IL-1β plays essential roles in brain function:
- Synaptic Plasticity: Low-level IL-1β signaling supports long-term potentiation (LTP) and memory formation
- Sleep Regulation: IL-1β participates in sleep-wake cycles and sleep homeostasis
- Neurogenesis: Modulates neural progenitor cell proliferation and differentiation
- Thermoregulation: Contributes to fever responses during infection
The cytokine maintains CNS immune vigilance:
- Microglial Activation: Baseline IL-1β maintains microglial surveillance state
- Response to Injury: Rapidly upregulated following CNS injury or infection
- Host Defense: Essential for protective inflammatory responses to pathogens
IL-1β is centrally implicated in AD pathogenesis through multiple mechanisms 2:
- Plaque Association: IL-1β colocalizes with amyloid-beta plaques in AD brain tissue
- APP Processing: IL-1β signaling increases amyloid precursor protein (APP) processing and Aβ production via NF-κB
- Aggregation Modulation: IL-1β affects Aβ aggregation kinetics and plaque formation
- NLRP3 Inflammasome: Aβ activates NLRP3, creating a feed-forward loop of IL-1β production 6
- Kinase Activation: IL-1β activates GSK3β and CDK5, key tau kinases
- Phosphorylation: Promotes tau phosphorylation at multiple AD-relevant sites (Ser396, Thr231, AT8)
- Tangle Formation: Facilitates tau aggregation and neurofibrillary tangle formation
- Spread Propagation: May contribute to tau pathology propagation between brain regions
- Synaptic Pruning: IL-1β promotes excessive microglial phagocytosis of synapses
- LTP Impairment: Chronic IL-1β exposure disrupts long-term potentiation
- Dendritic Spine Loss: Reduces dendritic spine density on hippocampal neurons
- Memory Deficits: IL-1β overexpression in hippocampus impairs spatial memory
- Microglial Activation: Sustains chronic microglial activation (" microglia)
- Cytokine Cascade: Triggers production of other pro-inflammatory cytokines (IL-6, TNF-α)
- Blood-Brain Barrier: Compromises BBB integrity, allowing peripheral immune cell infiltration
IL-1β contributes to PD through multiple mechanisms 15:
- Dopaminergic Neuron Loss: IL-1β is toxic to substantia nigra dopaminergic neurons
- Microglial Activation: Chronic activation of nigral microglia by IL-1β
- Inflammasome Activation: NLRP3 inflammasome in PD microglia produces IL-1β
- α-Synuclein Interplay: IL-1β accelerates α-synuclein aggregation and propagation
- Neuroinflammation: Elevated IL-1β in substantia nigra, CSF, and blood of PD patients
- Motor Neuron Toxicity: IL-1β directly damages upper and lower motor neurons
- Microglial Activation: Sustained neuroinflammatory response in spinal cord
- Disease Progression: IL-1β levels correlate with disease progression rate
- Therapeutic Target: IL-1R1 antagonists show promise in preclinical models
- Demyelination: IL-1β promotes oligodendrocyte death and demyelination
- Blood-Brain Barrier Breakdown: Facilitates leukocyte infiltration into CNS
- T-cell Activation: Supports Th1 and Th17 responses
- Disease Progression: IL-1β blockade reduces disease activity in MS models
- Tau Pathology: IL-1β contributes to tau phosphorylation and aggregation
- Neuroinflammation: Similar microglial activation patterns as AD
- Behavioral Symptoms: Cytokine-induced changes in frontal cortex function
- Anakinra (Kineret): Recombinant IL-1RA; FDA-approved for rheumatoid arthritis
- Canakinumab (Ilaris): Anti-IL-1β monoclonal antibody; approved for periodic fever syndromes
- Rilonacept (Arcalyst): IL-1R-Fc fusion protein; traps IL-1β and IL-1α
- AD Trials: Canakinumab failed in Phase 3 AD trial (CANTOS sub-study)
- PD Trials: Anakinra in early-phase PD trials (safety established, efficacy unclear)
- ALS Trials: IL-1 blockade showing mixed results in Phase 2
- NLRP3 Inhibitors: Targeting upstream inflammasome activation 6
- Small Molecule IL-1R1 Antagonists: Blood-brain barrier penetrant compounds
- Gene Therapy: AAV-delivered IL-1RA or IL-1R1 decoy
- MicroRNA-based: miR-155 antagonists to reduce IL-1β production
- CSF IL-1β: Elevated in AD, PD, and MS; potential diagnostic aid
- Blood IL-1β: Peripheral biomarker candidate (limited CNS specificity)
- PET Inflammation: IL-1R1 imaging for neuroinflammation visualization
- IL-1R1: Primary signaling receptor
- IL-1RAP: Accessory protein required for signaling
- MyD88: Downstream adaptor protein
- IRAK1/4: Kinase cascade members
- TRAF6: E3 ubiquitin ligase
- NLRP3: Pattern recognition receptor forming inflammasome
- ASC: Adaptor protein linking NLRP3 to caspase-1
- Pro-caspase-1: Zymogen for caspase-1 activation
- Gasdermin D: Pore-forming protein for IL-1β secretion
- IL-1RA: Natural antagonist
- IL-1R2: Decoy receptor
- SIGIRR: Single Ig IL-1R-related molecule (negative regulator)
| Model |
Description |
IL-1β Relevance |
Therapeutic Target |
| APP/PS1 mice |
AD model |
Elevated IL-1β near plaques |
IL-1R1 blockade |
| 5xFAD mice |
AD model |
Microglial IL-1β activation |
NLRP3 inhibitors |
| MPTP mice |
PD model |
Nigral IL-1β elevation |
IL-1RA |
| α-synuclein Tg |
PD model |
IL-1β in Lewy bodies |
Anti-IL-1β |
| SOD1 Tg mice |
ALS model |
Spinal cord IL-1β |
IL-1R1 antagonist |
| EAE mice |
MS model |
IL-1β drives demyelination |
NLRP3 inhibition |
- What triggers chronic IL-1β elevation in neurodegenerative disease?
- Is IL-1β cause or consequence of neurodegeneration?
- Can selective CNS IL-1β targeting avoid peripheral immunosuppression?
- What determines patient response to IL-1 blockade?
- Single-cell analysis: IL-1β production by specific microglial subsets
- Inflammasome imaging: PET ligands for NLRP3 visualization
- Personalized medicine: IL1B genetic variants affecting treatment response
- Combination therapy: IL-1 targeting with disease-modifying agents